Showing results (91-100 of 108) with videos related to

Sort By:
Pageof 11
Liver Cancer|April 22, 2026
Comparative Efficacy of Initial Treatment Strategies in Patients with Transarterial Chemoembolisation-Unsuitable Hepatocellular CarcinomaEdoardo G Giannini, Andrea Pasta, Giulia Pieri, et al.
Cancer Management and Research|January 7, 2022
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in ItalyValentina Burgio, Massimo Iavarone, Giovanni Giuseppe Di Costanzo, et al.
Scientific Reports|August 30, 2024
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus BevacizumabMargherita Rimini, Margarida Montes, Elisabeth Amadeo, et al.
Hepatology (Baltimore, Md.)|July 27, 2018
Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort StudyAlessandro Vitale, Fabio Farinati, Giulia Noaro, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 12, 2021
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinibIlario Giovanni Rapposelli, Toshifumi Tada, Shigeo Shimose, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 27, 2023
Quality of life in liver transplant recipients during the Corona virus disease 19 pandemic: A multicentre studyStefano Gitto, Lucia Golfieri, Nicolò Mannelli, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|May 27, 2024
A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and delta cohortLoreta A Kondili, Giuseppina Brancaccio, Maria Elena Tosti, et al.
International Journal of Cancer|November 23, 2023
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinomaFederico Rossari, Toshifumi Tada, Goki Suda, et al.
European Journal of Cancer (Oxford, England : 1990)|June 29, 2023
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patientsMara Persano, Margherita Rimini, Toshifumi Tada, et al.
Oncology|October 13, 2024
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World StudyMara Persano, Andrea Casadei-Gardini, Toshifumi Tada, et al.
Pageof 11